Find out how PSC is shaking things up by promoting senior officers!
The Public Service Commission (PSC) recently made waves in the prison sector by announcing the promotions of two senior officers. This move came in the wake of the retirements of Florence Omundi and Ken Aluda, paving the way for new leadership. Among the promoted officers, Maswai, who previously held the position of director of logistics at the prisons, was elevated to a higher role. Kiiri, who was in charge of the directorate, also received a well-deserved promotion. These changes signify a shift in leadership within the prison system, indicating a new direction for the institution.
In the realm of prison management, continuity and effective succession planning are crucial. The smooth transition following the retirements of Omundi and Aluda highlights the PSC's commitment to maintaining stability and efficiency within the prison service. It also showcases the talent development strategies implemented by the commission to ensure that capable individuals are ready to step into key positions at the right time. Such strategic decisions play a significant role in the overall functioning of the corrections sector, impacting the lives of both inmates and staff.
The appointment of Maswai and Kiiri to higher positions underscores the importance of experience and dedication in the field of prison administration. These individuals have proven their capabilities in their previous roles, earning recognition for their hard work and commitment. By promoting internal talent, the PSC not only rewards exceptional performance but also sends a message of encouragement to other officers to strive for excellence. This emphasis on meritocracy within the prison service fosters a culture of professionalism and drives continuous improvement in the delivery of correctional services.
The appointments followed the retirement of Flowrence Omundi and Ken Aluda. Maswai was the director logistics at the prisons while Kiiri headed the directorate ...
Mirum Pharmaceuticals is planning interim analyses in June of data from two Phase 2 trials testing volixibat in PSC and PBC patients.